25 October, 2019
Presentation Summary
Of the 1.37 million patients diagnosed with metastatic lung cancer in 2019, only 9,873 of them will have a NTRK gene fusion and be eligible for a targeted therapy that will likely have a significant impact on their quality of life. A lung cancer specialist in the US will only encounter 1 of these patients every 3 years. Through the course of this presentation, we are going to find those patients and save their lives.
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics.
Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.
Alma PR
71-73 Carter Lane
London
EC4V 5EQ.
| Tel: +44 (0)20 3405 0205 or [email protected] | ||
| Caroline Forde | Robyn Fisher | |
| Kieran Breheny |
